Form 4: RA Capital Reports Director Stock Option Grant at LENZ

RA Capital Management reports a stock option grant for Dr. Zachary Scheiner, a director at LENZ Therapeutics, Inc.

Summary

• RA Capital Management, L.P. filed a Form 4 disclosing the acquisition of 22,100 stock options by Dr. Zachary Scheiner.
• The options have an exercise price of $6.63 per share.
• The options were granted on June 15, 2026, and expire on June 15, 2036.
• The options vest in full on the earlier of June 15, 2027, or the date of the next annual meeting of stockholders.
• Dr. Scheiner holds these options for the benefit of RA Capital funds, with any proceeds used to offset advisory fees.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Alignment of interests between board members and institutional investors.
• Standard equity-based compensation for an outside director.

Negatives

• None identified.

Risks

• Vesting is contingent upon Dr. Scheiner's continued service as an Outside Director.
• The value of the options is subject to the market performance of LENZ common stock.

Future Outlook

The options vest in one year, contingent on continued board service.

Management Comments

• Dr. Scheiner is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation within the biotechnology sector, where institutional investors often place representatives on boards to oversee clinical and strategic development.

Comparison to Industry Standards

• The grant of stock options to non-executive directors is a standard practice in the life sciences industry to align board incentives with long-term shareholder value.
• The vesting schedule of one year is consistent with typical annual equity grants for board members in small-cap biotech firms.

Corporate Governance

Related Party Transactions

• Dr. Scheiner holds the options for the benefit of RA Capital funds, with proceeds offsetting advisory fees.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation arrangement.

Next Steps

• Vesting of options on June 15, 2027.

Key Dates

Keywords

LENZ Therapeutics, RA Capital Management, Form 4, Insider Trading, Stock Options, Biotech